Top Pharmaceuticals Bulk Drugs & Formulation Stocks India (Week of Sep 25, 2026)

Based on valuation and growth signals, these Pharmaceuticals Bulk Drugs & Formulation stocks show the strongest research merit

• Anlon Healthcare Ltd — Undervalued, PAT growth +133.2% YoY, earnings stable
• Amanta Healthcare Ltd — Fairly Valued, PAT growth -5.7% YoY, earnings stable
• Alivus Life Sciences Ltd — Overvalued, PAT growth +31.1% YoY, earnings stable
• Stocks sorted by valuation signal (most undervalued first).

Currently, 4 stocks in the Pharmaceuticals Bulk Drugs & Formulation sector are outperforming Nifty 500. This represents the sector's breadth — a higher count indicates broader sector participation in the market rally.

The Pharmaceuticals Bulk Drugs & Formulation sector is stable this week.

The Pharmaceuticals Bulk Drugs & Formulation stocks with the highest revenue growth

• Anlon Healthcare Ltd — Revenue growth +162.9% YoY
• Valiant Laboratories Ltd — Revenue growth +144.7% YoY
• Alivus Life Sciences Ltd — Revenue growth +6.3% YoY
• Amanta Healthcare Ltd — Revenue growth +5.3% YoY

The Pharmaceuticals Bulk Drugs & Formulation stocks with the highest profit growth

• Valiant Laboratories Ltd — PAT growth +950.0% YoY
• Anlon Healthcare Ltd — PAT growth +133.2% YoY
• Alivus Life Sciences Ltd — PAT growth +31.1% YoY
• Amanta Healthcare Ltd — PAT growth -5.7% YoY

1 stock in Pharmaceuticals Bulk Drugs & Formulation appears undervalued based on fair value analysis

• Anlon Healthcare Ltd — Undervalued

The average PE ratio of Pharmaceuticals Bulk Drugs & Formulation stocks with available data is 29x. This provides a benchmark for comparing individual stock valuations within the sector.

Earnings trend breakdown across Pharmaceuticals Bulk Drugs & Formulation (4 stocks with data)

• 4 stocks with stable earnings

Pharmaceuticals Bulk Drugs & Formulation shows mixed but improving signals — some stocks have strong fundamentals, worth selective study.

• Fundamentals: 0 of 4 stocks rated Very Strong/Strong, 2 Average, 2 Weak/Very Weak
• Profit growth: 3 stocks with PAT growing YoY, 1 declining
• Revenue growth: 4 of 4 stocks with positive revenue growth YoY
• Valuation: 1 stock appears undervalued

Pharmaceuticals Bulk Drugs & Formulation stocks with the longest outperformance streaks

• Amanta Healthcare Ltd — 9 weeks consecutive outperformance, PAT growth -5.7% YoY, Revenue +5.3% YoY
• Alivus Life Sciences Ltd — 4 weeks consecutive outperformance, PAT growth +31.1% YoY, Revenue +6.3% YoY
• Valiant Laboratories Ltd — 3 weeks consecutive outperformance, PAT growth +950.0% YoY, Revenue +144.7% YoY
• Anlon Healthcare Ltd — 2 weeks consecutive outperformance, PAT growth +133.2% YoY, Revenue +162.9% YoY

Pharmaceuticals Bulk Drugs & Formulation breadth trend over recent weeks

• Jul 10: 3 stocks outperforming
• Jul 19: 1 stock outperforming
• Aug 9: 2 stocks outperforming
• Aug 22: 3 stocks outperforming
• Sep 19: 4 stocks outperforming
• Sep 25: 4 stocks outperforming

Here is the current fundamental and growth snapshot for Pharmaceuticals Bulk Drugs & Formulation

• Fundamentals: 0 of 4 stocks rated Very Strong or Strong, 2 rated Weak or Very Weak
• Profit trend: 3 stocks with PAT growing YoY, 1 with profits declining
• Revenue trend: 4 stocks growing revenue, 0 seeing revenue decline
• 1 stock appears undervalued based on fair value analysis
• Market breadth: 4 stocks currently outperforming Nifty 500